|
Volumn 51, Issue 29, 2015, Pages 6301-6304
|
Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(iv) prodrug with unique mode of action
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CHALCONE;
CHALCOPLATIN;
CISPLATIN;
PLATINUM;
PLATINUM 195;
PRODRUG;
PROTEIN P53;
UNCLASSIFIED DRUG;
CHALCONE DERIVATIVE;
DNA;
PLATINUM COMPLEX;
ANTINEOPLASTIC ACTIVITY;
APOPTOSIS;
ARTICLE;
CELL MEMBRANE POTENTIAL;
COMPLEX FORMATION;
CONTROLLED STUDY;
DNA ADDUCT;
DNA DAMAGE;
DRUG ANALYSIS;
DRUG CYTOTOXICITY;
DRUG DNA BINDING;
DRUG DNA INTERACTION;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG SYNTHESIS;
ELECTROSPRAY MASS SPECTROMETRY;
FEMALE;
G2 PHASE CELL CYCLE CHECKPOINT;
HUMAN;
HUMAN CELL;
IC50;
IN VITRO STUDY;
NUCLEAR MAGNETIC RESONANCE;
PHASE 3 CLINICAL TRIAL (TOPIC);
PLATINUM NUCLEAR MAGNETIC RESONANCE;
PROTEIN DEGRADATION;
PROTEIN FUNCTION;
PROTEIN TARGETING;
S PHASE CELL CYCLE CHECKPOINT;
WESTERN BLOTTING;
CELL CYCLE;
DRUG EFFECTS;
HELA CELL LINE;
MCF 7 CELL LINE;
METABOLISM;
ANTINEOPLASTIC AGENTS;
CELL CYCLE;
CHALCONES;
DNA;
HELA CELLS;
HUMANS;
MCF-7 CELLS;
ORGANOPLATINUM COMPOUNDS;
PRODRUGS;
TUMOR SUPPRESSOR PROTEIN P53;
|
EID: 84925967704
PISSN: 13597345
EISSN: 1364548X
Source Type: Journal
DOI: 10.1039/c4cc10409a Document Type: Article |
Times cited : (92)
|
References (31)
|